

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tansey Casey M</u> (Last) (First) (Middle) 2802 FLINTROCK TRACE, SUITE 226 (Street) AUSTIN TX 78738 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 05/07/2026	3. Issuer Name and Ticker or Trading Symbol <u>Mobia Medical, Inc. [MOBI]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series F Preferred Stock	(1)	(1)	Common Stock	1,620,078	(1)	I	See Footnote ⁽²⁾⁽³⁾⁽⁴⁾
Series E-2 Preferred Stock	(1)	(1)	Common Stock	1,692,658	(1)	I	See Footnote ⁽²⁾⁽³⁾⁽⁴⁾
Convertible Notes	(5)	(5)	Common Stock	166,666	(5)	D	
Convertible Notes	(5)	(5)	Common Stock	314,090	(5)	I	By U.S. Venture Partners Select Fund I, L.P

Explanation of Responses:

- Each share of our Series F Preferred Stock and Series E-2 Preferred Stock will convert into Common Stock immediately prior to the completion of the Issuer's initial public offering pursuant to its terms.
- Consists of (i) 1,309,155 shares of Common Stock underlying Series F Preferred Stock held by U.S. Venture Partners Select Fund I, L.P. ("USVP SFI") on its own behalf and as a nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A" and, together with USVP SFI, the "USVP Select Funds"), (ii) 1,610,903 shares of Common Stock underlying Series E-2 Preferred Stock and 295,906 shares of Common Stock underlying Series F Preferred Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"), and (iii) 81,755 shares of Common Stock underlying Series E-2 Preferred Stock and 15,017 shares of Common Stock underlying Series F Preferred Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A" and, together with USVP XII, the "USVP XII Funds").
- Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of USVP XII and USVP XII-A and may be deemed to have sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of USVP SFI and USVP SFI-A and may be deemed to have sole voting and dispositive power with respect to the securities held by USVP SFI and USVP SFI-A.
- The Reporting Person is the managing partner and a managing member of each of PMG XII and PMG Select, and may be deemed to share voting and dispositive power with respect to the securities described herein. The Reporting Person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares.
- The Convertible Notes will automatically convert into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "Offering"). The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.

Remarks:

Exhibit 24 - Power of Attorney.

/s/ Chase Leavitt,
Attorney-in-Fact

05/07/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

MOBIA MEDICAL, INC.
POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Mobia Medical, Inc. (the “Company”), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned’s true and lawful attorney-in-fact to:

1. execute for and on behalf of the undersigned, Schedules 13D and 13G in accordance with Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder, and Forms 3, 4, and 5 in accordance with Section 16 of the Exchange Act and the rules thereunder, and Notices of Proposed Sale of Securities Pursuant to Rule 144 (“Form 144”), in accordance with the requirements of Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”); and
2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, complete and execute any amendment or amendments thereto, and to timely file such Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144, as applicable, and any amendment thereto, with the United States Securities and Exchange Commission and any stock exchange or similar authority.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 and Section 16 of the Exchange Act, or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Schedule 13D, Schedule 13G, Form 3, Form 4, Form 5, and Form 144 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 6, 2026.

/S/ Casey M. Tansey

Casey M. Tansey

Schedule A

**INDIVIDUALS APPOINTED AS ATTORNEY-IN-FACT,
WITH FULL POWER OF SUBSTITUTION AND RESUBSTITUTION**

1. Richard Foust
2. Bunker Curnes
3. Chase Leavitt